Loading
Latest filing published 21 Feb 2024 for Genprex, Inc., €11k.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John Rodney Varner appears in our data through filings on Genprex, Inc. shares, published by SEC (Form 4). The record holds 5 filings, for trades running from 29 March 2018 to 18 February 2024.
No open-market sale appears; the market trades are 3 purchases worth €60k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants.
Half of the purchases are above €18k and half below. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 3 purchases show a median change of -3.9%, with the price up in 33% of them. These figures describe past trades and do not predict future prices.
The latest filing, published on 21 February 2024, reports a share grant of €11k in Genprex, Inc. The clock since the last published purchase (24 April 2023) now reads 1,281 days. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations